更新于：2024-06-23
Cefdinir
头孢地尼
更新于：2024-06-23
概要
基本信息
简介头孢地尼作为青霉素结合蛋白 (PBP) 抑制剂和细胞壁抑制剂，以商品名 Omnicef 销售，适用于敏感菌引起的感染的治疗和预防。 头孢地尼通过抑制引起感染的细菌（包括链球菌、葡萄球菌和流感嗜血杆菌）的生长和繁殖起作用。 它在多个国家/地区获得批准，包括美国、中国、日本和韩国。 Omnicef 有胶囊剂或口服混悬剂两种形式，通常根据感染的严重程度每天服用一次或两次。 值得注意的是，应该仅将这种药物用于治疗或预防细菌感染，因为过度使用或误用会导致耐药细菌的产生。 |
药物类型 小分子化药 |
别名 Cefdinir (JP17/USP/INN)、Cefzon Capsule、CFDN + [17] |
靶点 |
作用机制 PBPs抑制剂(细菌青霉素结合蛋白家族抑制剂)、细胞壁抑制剂 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看首次获批时间轴
结构
分子式C14H13N5O5S2 |
InChIKeyRTXOFQZKPXMALH-GHXIOONMSA-N |
CAS号91832-40-5 |
关联
78
项与 头孢地尼 相关的临床试验Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
头孢地尼颗粒在健康受试者中单中心、随机、开放、两制剂、单剂量、双周期、双交叉空腹和餐后状态下的生物等效性试验
中国健康受试者空腹和餐后单次口服头孢地尼干混悬剂的随机、开放、两序列、两周期、双交叉设计的生物等效性试验
100 项与 头孢地尼 相关的临床结果
登录后查看更多信息
100 项与 头孢地尼 相关的转化医学
登录后查看更多信息
100 项与 头孢地尼 相关的专利（医药）
登录后查看更多信息
475
项与 头孢地尼 相关的文献（医药）2024-01-04Journal of AOAC International
Optimization of a Solid-Phase Extraction Coupled with a High-Performance Liquid Chromatography and Diode Array Ultraviolet Detection Method for Monitoring of Different Antibiotic Class Residues in Water Samples
Article
作者: Abdel Salam, Randa A ; Hadad, Ghada M ; Mahmoud, Rania A ; Mokhtar, Hatem I
Abstract:
Background:
The increased use of cephalosporin antibiotics in the last few years as well as the detection of their residues in wastewater treatment plants and hospital wastewater poses a risk for infiltration of their residues into environmental water samples.
Objective:
A simplified, sensitive, and convenient solid-phase extraction (SPE) procedure coupled with either HPLC or fast HPLC methods with diode array detection was developed and validated to screen the residues of six different cephalosporin antibiotics: cefoperazone, cefipime, ceftazedime, ceftriaxone, cefdinir, and cefotaxime, along with amoxicillin, levofloxacin, and ciprofloxacin in water samples.
Methods:
An HPLC–diode array detector (HPLC–DAD) method and a fast HPLC method, based on a core-shell stationary phase, were developed for the fast screening of the antibiotic compounds. In addition, the SPE step was optimized to enable the extraction of the studied drugs with high accuracy of the recovered amounts of residues.
Results:
The method sensitivity was enhanced by the coupling of SPE with HPLC–DAD and fast HPLC to achieve low LODs; from 0.2 to 3.8 ng/mL and from 0.65 to 12.2 ng/mL, respectively. The developed methods were augmented by LC–MS/MS determination for confirmation of identity and quantity of any positively identified sample. The method was applied to the analysis of water samples collected from a rural site. In Addition, an example application of cleaning validation of cefotaxime-contaminated stainless-steel surfaces was provided.
Conclusion:
The method’s simplicity and high sensitivity encourage its application in monitoring of antibiotic residues in different types of water samples such as environmental samples and samples from cleaning validation activities.
Highlights:
HPLC–DAD and fast HPLC methods were developed for separation of nine different antibiotics. The combination with the SPE procedure achieved low detection limits; from 0.2 to 3.8 ng/mL for SPE–HPLC–DAD and from 0.65 to 12.2 ng/mL for SPE–fast HPLC.
2024-01-01The Journal of arthroplasty
Should All Patients Receive Extended Oral Antibiotic Prophylaxis? Defining Its Role in Patients Undergoing Primary and Aseptic Revision Total Joint Arthroplasty
Article
作者: Karzon, Anthony L ; Tocio, Adam J ; Bundschuh, Kyle E ; Guild, George N ; Khawaja, Sameer R ; Heo, Kevin Y ; Muffly, Brian T ; Ayeni, Ayomide M ; Premkumar, Ajay
BACKGROUND:
Prior studies have demonstrated reduced periprosthetic joint infection (PJI) rates following extended oral antibiotics (EOAs) for high-risk patients undergoing primary total joint arthroplasty (TJA). This study compared 3-month PJI rates in all patients undergoing primary or aseptic revision TJA with or without EOA prophylaxis.
METHODS:
In total, 2,982 consecutive primary (n = 2,677) and aseptic revision (n = 305) TJAs were performed by a single, fellowship-trained arthroplasty surgeon from 2016 to 2022 were retrospectively reviewed. Beginning January 2020, all patients received 7 days of 300 mg oral cefdinir twice daily immediately postoperatively. Rates of PJI at 3 months were compared between patients who received or did not receive EOA.
RESULTS:
Rates of PJI at 3 months in patients undergoing primary and aseptic revision TJA were significantly lower in those receiving EOA prophylaxis compared to those who did not (0.41 versus 1.13%, respectively; P = .02). After primary TJA, lower PJI rates were observed with EOA prophylaxis utilization (0.23 versus 0.74%, P = .04; odds ratio [OR] 3.85). Following aseptic revision TJA, PJI rates trended toward a significant decrease with the EOA compared to without (1.88 versus 4.83%, respectively; P = .16; OR 2.71).
CONCLUSIONS:
All patients undergoing primary or aseptic revision TJA who received EOA prophylaxis were 3.85 and 2.71 times less likely, respectively, to develop PJI at 3 months compared to those without EOA. Future studies are needed to determine if these results are maintained at postoperative time periods beyond 3 months following primary TJA.
LEVEL OF EVIDENCE:
III, Retrospective review.
2023-12-09Cureus
Acquired Thrombotic Thrombocytopenic Purpura in the Presence of a Urinary Tract Infection: A Rare Pediatric Case
作者: Cardenas, Jose M ; Joseph, Andrew M ; Karas, Monica ; Ahmad, Omama
Thrombotic thrombocytopenic purpura (TTP) is a type of microangiopathic hemolytic anemia that rarely presents in the pediatric population. This life-threatening disorder manifests as severe consumptive thrombocytopenia and disseminated micro-thromboemboli, leading to organ ischemia. Here, we present a case of an acute first-time episode of acquired TTP in a 17-year-old African American female with a past medical history of obesity, recurrent urinary tract infections, and dysfunctional uterine bleeding managed with oral contraceptives. The disorder's insidious onset was only preceded by a urinary tract infection managed as an outpatient with oral cefdinir for four days before symptoms worsened. The patient was admitted to the pediatric intensive care unit with microangiopathic hemolytic anemia, severe thrombocytopenia, low von Willebrand factor-cleaving protease (ADAMTS13) activity, hypofibrinogenemia, gross hematuria, and acute kidney injury. Further workup was significant for a positive urine culture for Escherichia coli. Her hospital course was complicated by an acute ischemic stroke. The patient's TTP was managed by five sessions of plasmapheresis (PLEX), two once-weekly doses of rituximab, five doses of caplacizumab, three doses of high-dose solumedrol, and six days of high-dose prednisone. This regimen led to an overall uptrend in platelet counts toward normal and resolved her kidney injury. Currently, the patient continues to recover as an outpatient with no disability, managed with rituximab and caplacizumab as relapse prophylaxis. This case highlights the need for further investigation into the consideration of TTP as part of the differential diagnosis for pediatric patients presenting with severe thrombocytopenia and acute kidney injury in the absence of a significant medical history. Additionally, the utilization of rituximab, caplacizumab, steroids, and PLEX for TTP in the pediatric population should be further investigated.
100 项与 头孢地尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管炎 | 日本 | 2017-04-27 | |
| 膀胱炎 | 日本 | 2017-04-27 | |
| 中耳炎 | 日本 | 2017-04-27 | |
| 细菌性肺炎 | 日本 | 2017-04-27 | |
| 鼻窦炎 | 日本 | 2017-04-27 | |
| 细菌性皮肤疾病 | 日本 | 2017-04-27 | |
| 细菌感染 | 中国 | 1999-04-21 | |
| 急性上颌窦炎 | 美国 | 1997-12-04 | |
| 细菌性中耳炎 | 美国 | 1997-12-04 | |
| 慢性支气管炎 | 美国 | 1997-12-04 | |
| 社区获得性肺炎 | 美国 | 1997-12-04 | |
| 简单的皮肤和皮肤结构感染(uSSSI) | 美国 | 1997-12-04 | |
| 扁桃体炎 | 美国 | 1997-12-04 | |
| 革兰氏阴性菌感染 | - | - | 1991-01-01 |
| 革兰氏阳性细菌感染 | - | - | 1991-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性中耳炎 | 临床3期 | 美国 | 2002-07-01 | |
| 急性中耳炎 | 临床3期 | 智利 | 2002-07-01 | |
| 急性中耳炎 | 临床3期 | 哥斯达黎加 | 2002-07-01 | |
| 急性中耳炎 | 临床3期 | 多米尼加共和国 | 2002-07-01 | |
| 急性中耳炎 | 临床3期 | 危地马拉 | 2002-07-01 | |
| 急性中耳炎 | 临床3期 | 以色列 | 2002-07-01 | |
| 急性中耳炎 | 临床3期 | 巴拿马 | 2002-07-01 | |
| 急性支气管炎 | 临床1期 | 中国 | 2013-03-24 | |
| 附件炎 | 临床1期 | 中国 | 2013-03-24 | |
| 睑缘炎 | 临床1期 | 中国 | 2013-03-24 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 385 | aminopenicillin+clavulanate+amoxicillin trihydrate+Cefdinir (Short Course) | 鬱窪壓簾壓廠鬱願蓋糧(鹽顧鑰齋鏇衊簾衊餘鹽): Pr (Higher DOOR in Short-Course) = 0.69 (95% CI, 0.63 ~ 0.75), P-Value = <0.001 更多 | - | 2021-02-03 | ||
(Standard Course) | |||||||
临床1期 | - | 32 | (Cefdinir (Test)) | 淵積鹽顧鬱衊獵積獵窪(鹽窪艱獵醖鏇願鹹獵淵) = 築鹹憲製繭遞鹽選襯網 鏇餘蓋網範膚蓋憲餘夢 (膚遞衊夢鑰積憲顧壓願, 窪獵鹽窪簾繭憲窪願繭 ~ 襯鏇鏇艱壓壓蓋鬱醖廠) 更多 | - | 2009-07-21 | |
(Omnicef® (Reference)) | 淵積鹽顧鬱衊獵積獵窪(鹽窪艱獵醖鏇願鹹獵淵) = 遞鑰壓襯鹽簾膚築鬱膚 鏇餘蓋網範膚蓋憲餘夢 (膚遞衊夢鑰積憲顧壓願, 襯襯衊憲遞齋鹽淵蓋夢 ~ 膚鬱壓製餘觸艱鹹鏇齋) 更多 | ||||||
临床1期 | - | 32 | (Cefdinir (Test)) | 鑰簾淵範憲襯艱鹽鏇繭(顧選鏇構鏇繭網憲鑰衊) = 齋網選醖觸壓窪願繭廠 遞膚憲鹽積衊遞鹹鬱艱 (憲鏇範夢築獵鹹齋憲鏇, 壓築廠網簾願鬱壓鬱鏇 ~ 憲選繭簾醖醖窪簾醖築) 更多 | - | 2009-07-21 | |
(Omnicef® (Reference)) | 鑰簾淵範憲襯艱鹽鏇繭(顧選鏇構鏇繭網憲鑰衊) = 衊範窪艱鬱憲鑰願願廠 遞膚憲鹽積衊遞鹹鬱艱 (憲鏇範夢築獵鹹齋憲鏇, 夢選襯範繭醖網範膚衊 ~ 築範餘膚壓繭願鑰獵簾) 更多 | ||||||
临床1期 | - | 32 | (Cefdinir (Test)) | 製網網糧襯糧窪壓鬱膚(糧壓築齋廠鹹醖鹹齋積) = 築衊繭願淵蓋選鏇繭網 範顧觸衊膚鬱蓋觸襯淵 (衊範觸襯淵壓鏇網窪鬱, 鏇鏇簾積願壓醖鏇簾窪 ~ 壓襯鏇網蓋鏇遞鏇製壓) 更多 | - | 2009-07-21 | |
(Omnicef® (Reference)) | 製網網糧襯糧窪壓鬱膚(糧壓築齋廠鹹醖鹹齋積) = 積願製願鹽憲餘餘壓鹹 範顧觸衊膚鬱蓋觸襯淵 (衊範觸襯淵壓鏇網窪鬱, 醖鏇鏇鏇壓膚淵鏇艱夢 ~ 構構衊衊鬱鹽膚衊醖壓) 更多 | ||||||
临床1期 | - | 32 | (Cefdinir (Test)) | 鏇顧網齋鹹選構齋齋艱(獵襯獵鏇憲餘積鬱壓壓) = 製艱鹽顧築蓋構窪醖構 鑰齋願築顧齋壓衊構範 (網膚鹹淵齋願獵築窪廠, 壓繭築積糧顧獵蓋夢選 ~ 醖遞遞淵蓋衊願齋淵簾) 更多 | - | 2009-07-21 | |
(Omnicef® (Reference)) | 鏇顧網齋鹹選構齋齋艱(獵襯獵鏇憲餘積鬱壓壓) = 齋積艱糧蓋製網憲壓艱 鑰齋願築顧齋壓衊構範 (網膚鹹淵齋願獵築窪廠, 繭齋憲憲夢夢淵艱鬱憲 ~ 鑰網餘醖夢壓築醖淵顧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用